Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jaguar Animal Health (JAGX)
NASDAQ:JAGX
Holding JAGX?
Track your performance easily
JAGX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.84 - $21.60
Previous Close$0.93
Volume529.16K
Average Volume (3M)360.91K
Market Cap
$10.30M
Enterprise Value$30.79M
Total Cash (Recent Filing)$13.27M
Total Debt (Recent Filing)$34.27M
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Apr 15, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.10
Shares Outstanding11,798,288
10 Day Avg. Volume806,377
30 Day Avg. Volume360,911
Standard Deviation0.52
R-Squared0.00834
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.81
Price to Sales (P/S)0.98
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.84
Enterprise Value/Gross Profit3.99
Enterprise Value/Ebitda-1.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Jaguar Animal Health News
Ownership Overview
2.84% Insiders
1.02% Mutual Funds
0.22% Other Institutional Investors
95.42% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
JAGX FAQ
What was Jaguar Animal Health’s price range in the past 12 months?
Jaguar Animal Health lowest stock price was $0.84 and its highest was $21.60 in the past 12 months.
What is Jaguar Animal Health’s market cap?
Currently, no data Available
When is Jaguar Animal Health’s upcoming earnings report date?
Jaguar Animal Health’s upcoming earnings report date is Apr 15, 2025 which is in 114 days.
How were Jaguar Animal Health’s earnings last quarter?
Jaguar Animal Health released its earnings results on Nov 13, 2024. The company reported -$1.05 earnings per share for the quarter, beating the consensus estimate of -$2.37 by $1.32.
Is Jaguar Animal Health overvalued?
According to Wall Street analysts Jaguar Animal Health’s price is currently Overvalued.
Does Jaguar Animal Health pay dividends?
Jaguar Animal Health does not currently pay dividends.
What is Jaguar Animal Health’s EPS estimate?
Jaguar Animal Health’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jaguar Animal Health have?
Jaguar Animal Health has 11,798,288 shares outstanding.
What happened to Jaguar Animal Health’s price movement after its last earnings report?
Jaguar Animal Health reported an EPS of -$1.05 in its last earnings report, beating expectations of -$2.37. Following the earnings report the stock price went down -9.174%.
Which hedge fund is a major shareholder of Jaguar Animal Health?
Currently, no hedge funds are holding shares in JAGX
---
Jaguar Animal Health Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
JAGX Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.72%
12-Months-Change
Fundamentals
Return on Equity
-432.40%
Trailing 12-Months
Asset Growth
28.84%
Trailing 12-Months
Company Description
Jaguar Animal Health
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
---
JAGX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth and promising clinical trial results, particularly in the area of cancer treatment. However, the company's increased net loss and non-GAAP recurring EBITDA loss indicate financial challenges. The achievements in drug development and product launches suggest potential future growth, but financial improvements are necessary.Read More>---
Technical Analysis
---